# Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav … – Investors > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pharmaceutical-cbd-research-epidiolex-studies/ > **Published:** 2026-04-09T12:10:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:26:42-04:00 > **Clinical Summary:** Explore pharmaceutical CBD research with Jazz Pharmaceuticals' latest Epidiolex studies advancing epilepsy treatment and off-label prescribing insights. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic EpilepsyCbdPediatricsPharmaceuticalFda Why This Matters Jazz Pharmaceuticals’ continued research presentations on Epidiolex represent ongoing expansion of evidence-based [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/) beyond its FDA-approved pediatric epilepsy indications. These studies may inform off-label prescribing decisions and future regulatory pathways for pharmaceutical CBD. Clinical Summary Jazz Pharmaceuticals is presenting additional research on Epidiolex (pharmaceutical-grade CBD) at upcoming medical conferences. Epidiolex remains the only FDA-approved cannabis-derived medication, currently indicated for seizures associated with Lennox-Gastaut syndrome, [Dravet syndrome](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/), and tuberous sclerosis complex in patients 1 year and older. The company continues to investigate potential applications beyond these approved epilepsy syndromes, though specific study details were not provided in this announcement. Dr. Caplan’s Take “While I appreciate rigorous pharmaceutical research on cannabinoids, clinicians should remember that Epidiolex’s success in specific pediatric epilepsy syndromes doesn’t automatically translate to other conditions. The real clinical value lies in understanding which patients might benefit from pharmaceutical-grade CBD versus other [cannabinoid formulations](https://cedclinic.com/brazil-cannabis-regulatory-framework-new-medical-rules/).” Clinical Perspective 🧠 Clinicians prescribing Epidiolex should focus on its established efficacy in approved indications rather than speculating about emerging research. For patients with treatment-resistant epilepsy in the approved categories, Epidiolex offers a well-characterized option with known drug interactions and dosing protocols. Any off-label considerations should be evidence-guided and carefully monitored. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Jazz%20Pharmaceuticals%20to%20Present%20Research%20on%20Epidiolex%C2%AE%20%28cannabidiol%29%20and%20Xywav%20....%20%40drcaplan&url=https%3A//investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-research-epidiolexr-cannabidiol-and)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-research-epidiolexr-cannabidiol-and)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Jazz%20Pharmaceuticals%20to%20Present%20Research%20on%20Epidiolex%C2%AE%20%28cannabidiol%29%20and%20Xywav%20....%20--%20via%20%40drcaplan.bsky.social%20https%3A//investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-research-epidiolexr-cannabidiol-and)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-research-epidiolexr-cannabidiol-and](https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-research-epidiolexr-cannabidiol-and) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis research?](#What_is_the_clinical_relevance_rating_for_this_cannabis_research) - [What medical conditions does this research focus on?](#What_medical_conditions_does_this_research_focus_on) - [What type of cannabis compound is being studied?](#What_type_of_cannabis_compound_is_being_studied) - [Is this research related to pharmaceutical development?](#Is_this_research_related_to_pharmaceutical_development) - [Why is this considered newsworthy for clinicians?](#Why_is_this_considered_newsworthy_for_clinicians) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis research? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the findings represent emerging developments or policy changes that healthcare professionals should monitor closely. #### What medical conditions does this research focus on? The research primarily focuses on epilepsy treatment, particularly in pediatric patients. The study examines the therapeutic applications of CBD in managing seizure disorders in children. #### What type of cannabis compound is being studied? The research specifically examines CBD (cannabidiol), a non-psychoactive compound found in cannabis. CBD has shown promise in treating various medical conditions, particularly epilepsy and seizure disorders. #### Is this research related to pharmaceutical development? Yes, this appears to be pharmaceutical research focusing on CBD as a medical treatment. The study likely examines standardized, medical-grade CBD formulations rather than recreational cannabis products. #### Why is this considered newsworthy for clinicians? This research represents emerging findings in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) that could impact clinical practice. Healthcare providers need to stay informed about CBD’s therapeutic potential and regulatory developments affecting patient treatment options. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [FDA-Approved CBD Drug Shows Early Promise in Anorexia Patients](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) Learn about the promising early results of FDA-approved CBD drugs in treating anorexia, highlighting the expanding therapeutic potential of pharmaceutical CBD. [Read More](https://cedclinic.com/fda-approved-cbd-drug-anorexia-promise/) [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) Explore how cannabinoids, including pharmaceutical CBD, are integrated into [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) and the latest research developments in [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/). [Explore Now](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) [Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav …](https://cedclinic.com/pharmaceutical-grade-cbd-research-epidiolex-xywav/) Stay updated on Jazz Pharmaceuticals' presentations about Epidiolex and Xywav, focusing on pharmaceutical CBD research and epilepsy treatment. [Learn More](https://cedclinic.com/pharmaceutical-grade-cbd-research-epidiolex-xywav/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).